GET DAILY SIGNALSWhy Is Maze Therapeutics (MAZE) Stock Down -5.65% Today?
Key Takeaways
- MAZE fell 5.65% to $34.05 in early Friday trading, a decline of $2.04 from Thursday's close of $36.09.
- No verified company-specific catalyst: no new release, filing, clinical update, or analyst action accompanied the drop.
- The primary driver appears to be profit-taking after a roughly 64% run from the Sept. 21 close of $22.39 to the Nov. 11 close of $36.73.
- Third-quarter results, published Nov. 9, showed a wider net loss of $48.0 million and a 60% jump in R&D spending — a backdrop, not the trigger, since the stock rallied for three sessions afterward.
- Trading was heavy relative to the tape, with roughly 91,000 shares changing hands in the first 20 minutes, about three times the recent pace.
- News Significance Score: 14/100 — no fresh news and a drop only about twice the stock's typical daily swing.
- Attention now turns to the Jefferies healthcare conference on Nov. 17 and the early-2027 HORIZON data timeline.
- For deeper detail, explore Price Targets, Earnings, and Forecast pages dedicated to the stock.
- Readers can also review curated model portfolios on the Trending AI Robots page.
Opening Summary
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company based in South San Francisco that uses human genetics to design oral small-molecule medicines for kidney and metabolic disease. Its lead assets are MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, an SLC6A19 inhibitor in Phase 2 for phenylketonuria and chronic kidney disease.
Shares of MAZE were trading at $34.05 shortly after the opening bell, down $2.04, or 5.65%, from the prior session's close of $36.09. The direction is unambiguously lower. The stock opened at $35.25, slid as far as $32.53 — a decline of nearly 10% at the low — and then pared the loss. No verified news catalyst was identified for the move.
No Verified Catalyst: A Pullback After a Sharp Run
No verified news or fundamental catalyst found for Friday's decline. There was no company press release, no 8-K, no regulatory update, no clinical data readout, and no analyst rating change tied to the session. The most likely explanation is mechanical and technical rather than fundamental: a fast-money exit after an extended advance in a thinly traded, high-beta clinical-stage name.
The setup is consistent with profit-taking. MAZE closed at $22.39 on Sept. 21 and at $36.73 on Nov. 11, a gain of roughly 64% in about seven weeks, including a 7.88% jump on Oct. 19 and a 9.26% jump on Oct. 20. It touched $37.41 on Nov. 11, its highest level since spring, and then slipped 1.74% on Nov. 12 before Friday's deeper retreat. When a micro-cap biotech doubles-digit runs on modest liquidity, the exit of a single large holder or the unwinding of momentum positions can move the tape by several percent without any news.
The fundamental backdrop is not new. Third-quarter results published Nov. 9 showed a net loss of $48.0 million, or $0.79 per share, versus $30.1 million a year earlier, as research and development spending climbed 60% to $40.2 million. Cash, equivalents, and marketable securities stood at $477 million, which management says funds operations into 2029. Enrollment in the Phase 2 HORIZON trial of MZE829 is complete with more than 50 patients, final data are expected in early 2027, and a pivotal trial is planned for the first half of 2027. Investors largely looked through the wider loss — the stock rose for three consecutive sessions after the report — so the report is context for the pullback, not its cause. A modest trim to a sell-side price target earlier in the week, with the Overweight rating maintained, likewise does not explain a move of this size.
Technically, the intraday low of $32.53 held above the 200-day moving average near $31.50 and above the Nov. 4 low of about $32.10, and the stock remains roughly 37% below its 52-week high of $53.65. That combination — support respected, but a sharp failure at the $37 area — fits a consolidation pattern rather than a change in the investment case.
Market Context and Trading Activity
Volume was elevated. Roughly 91,000 shares traded in the first 20 minutes, a pace more than three times the norm for that point in the session, against a recent average daily volume near 700,000 shares. Heavier-than-normal turnover on a down day suggests active position reduction rather than passive drift.
The move was idiosyncratic in the sense that it was not accompanied by any sector-wide announcement, peer readout, or macro data release specific to kidney disease or metabolic medicine. Small- and mid-cap biotechnology has been volatile through the autumn, and single-name swings of 5% to 10% remain common in the group. The session's range of about 7.5% is wide but well within the stock's recent behavior; the shares have posted moves of 5.65% or more six times in the last 60 sessions, including a 26.75% surge on Sept. 22 and a 6.69% drop on Sept. 24.
News Significance Score
On a scale where 0 means no meaningful news behind a routine move and 100 means transformative news behind an extreme, rare move, MAZE scores 14 out of 100. No verified news was identified for the session, and the most recent fundamental update — third-quarter results on Nov. 9 — was followed by three straight up days, which undercuts it as an explanation for Friday's selling.
The decline of 5.65% was roughly 2.1 times the stock's typical daily move of about 2.7%, and moves of that magnitude have occurred six times in the past 60 sessions. A weak catalyst combined with a moderately unusual but not exceptional price swing produces a low score.
What Comes Next for MAZE
The calendar is thin on hard catalysts until next year. Management is scheduled to present at the Jefferies Global Healthcare Conference in London on Nov. 17 and at the Evercore Healthcare Conference on Dec. 1, appearances that often generate incremental commentary on trial enrollment, dosing strategy, and regulatory planning. Fourth-quarter and full-year 2026 financial results are expected in March 2027.
The decisive events remain clinical: final HORIZON data across three APOL1-mediated kidney disease cohorts in early 2027, initiation of a pivotal program in the first half of 2027 subject to regulatory feedback, and topline CIPheR data for MZE782 in phenylketonuria during 2027. Risks include slower-than-expected enrollment or site activation, spending that outpaces the current runway guidance, competitive APOL1 programs from larger developers, and the sensitivity of a sub-$2 billion market capitalization to financing conditions. With no revenue base beyond a one-time licensing milestone, sentiment will continue to hinge on execution against those 2027 milestones.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies in the current market environment. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the best performers under prevailing conditions are featured in this section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the list changes as market conditions shift. Reviewing the trending lineup is a practical way to see which approaches are working right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for MAZE turns positive, indicating new upward trend
MAZE saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator turned positive. In 31 of the 33 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
MAZE moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MAZE crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +5.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where MAZE advanced for three days, in 92 of 104 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 66 of 80 cases where MAZE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAZE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
MAZE broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.191) is normal, around the industry mean (3.498). P/E Ratio (-14.012) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MAZE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAZE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement